These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 31217905)

  • 21. Novel anti-angiogenic therapies for malignant gliomas.
    Norden AD; Drappatz J; Wen PY
    Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glucose-regulated protein 78 silencing down-regulates vascular endothelial growth factor/vascular endothelial growth factor receptor 2 pathway to suppress human colon cancer tumor growth.
    Kuo LJ; Hung CS; Chen WY; Chang YJ; Wei PL
    J Surg Res; 2013 Nov; 185(1):264-72. PubMed ID: 23759331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumour angiogenesis: a novel therapeutic target in patients with malignant disease.
    O'Byrne KJ; Steward WP
    Expert Opin Emerg Drugs; 2001 Apr; 6(1):155-74. PubMed ID: 15989502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ginsenoside Rg3 targets cancer stem cells and tumor angiogenesis to inhibit colorectal cancer progression in vivo.
    Tang YC; Zhang Y; Zhou J; Zhi Q; Wu MY; Gong FR; Shen M; Liu L; Tao M; Shen B; Gu DM; Yu J; Xu MD; Gao Y; Li W
    Int J Oncol; 2018 Jan; 52(1):127-138. PubMed ID: 29115601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ursolic acid inhibits colorectal cancer angiogenesis through suppression of multiple signaling pathways.
    Lin J; Chen Y; Wei L; Hong Z; Sferra TJ; Peng J
    Int J Oncol; 2013 Nov; 43(5):1666-74. PubMed ID: 24042330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models.
    El-Emir E; Dearling JL; Huhalov A; Robson MP; Boxer G; Neri D; van Dongen GA; Trachsel E; Begent RH; Pedley RB
    Br J Cancer; 2007 Jun; 96(12):1862-70. PubMed ID: 17519905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
    Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K
    Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular endothelial growth factor overproduced by tumour cells acts predominantly as a potent angiogenic factor contributing to malignant progression.
    Aonuma M; Saeki Y; Akimoto T; Nakayama Y; Hattori C; Yoshitake Y; Nishikawa K; Shibuya M; Tanaka NG
    Int J Exp Pathol; 1999 Oct; 80(5):271-81. PubMed ID: 10607018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypoxia-induced angiogenesis and vascular endothelial growth factor secretion in human melanoma.
    Rofstad EK; Danielsen T
    Br J Cancer; 1998 Mar; 77(6):897-902. PubMed ID: 9528831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
    Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
    Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hedyotis diffusa Willd extract suppresses Sonic hedgehog signaling leading to the inhibition of colorectal cancer angiogenesis.
    Lin J; Wei L; Shen A; Cai Q; Xu W; Li H; Zhan Y; Hong Z; Peng J
    Int J Oncol; 2013 Feb; 42(2):651-6. PubMed ID: 23291612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
    Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
    Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DDA suppresses angiogenesis and tumor growth of colorectal cancer in vivo through decreasing VEGFR2 signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Oncotarget; 2016 Sep; 7(39):63124-63137. PubMed ID: 27517319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin-(1-7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1.
    Krishnan B; Torti FM; Gallagher PE; Tallant EA
    Prostate; 2013 Jan; 73(1):60-70. PubMed ID: 22644934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T11TS inhibits Angiopoietin-1/Tie-2 signaling, EGFR activation and Raf/MEK/ERK pathway in brain endothelial cells restraining angiogenesis in glioma model.
    Bhattacharya D; Chaudhuri S; Singh MK; Chaudhuri S
    Exp Mol Pathol; 2015 Jun; 98(3):455-66. PubMed ID: 25797371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis.
    Achen MG; Williams RA; Minekus MP; Thornton GE; Stenvers K; Rogers PA; Lederman F; Roufail S; Stacker SA
    J Pathol; 2001 Feb; 193(2):147-54. PubMed ID: 11180159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Semaphorin-plexin signalling genes associated with human breast tumourigenesis.
    Gabrovska PN; Smith RA; Tiang T; Weinstein SR; Haupt LM; Griffiths LR
    Gene; 2011 Dec; 489(2):63-9. PubMed ID: 21925246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tanshinone IIA inhibits β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in normoxic and HIF-1α in hypoxic microenvironments in human colorectal cancer.
    Sui H; Zhao J; Zhou L; Wen H; Deng W; Li C; Ji Q; Liu X; Feng Y; Chai N; Zhang Q; Cai J; Li Q
    Cancer Lett; 2017 Sep; 403():86-97. PubMed ID: 28602978
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors.
    Stoeltzing O; Ahmad SA; Liu W; McCarty MF; Wey JS; Parikh AA; Fan F; Reinmuth N; Kawaguchi M; Bucana CD; Ellis LM
    Cancer Res; 2003 Jun; 63(12):3370-7. PubMed ID: 12810673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways.
    Greening DW; Lee ST; Ji H; Simpson RJ; Rigopoulos A; Murone C; Fang C; Gong S; O'Keefe G; Scott AM
    Oncotarget; 2015 Nov; 6(35):38166-80. PubMed ID: 26517691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.